Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($2.32), $1.37 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $254.7 million versus the consensus estimate of $190 million.

GUIDANCE

Emergent BioSolutions sees FY2024 revenue of $1.050 - $1.125 billion versus the consensus of $1.033 billion

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.